In a recent interview, the CEO of Instadeep, Africa's largest AI startup, compared the current state of biology AI to the early days of GPT technology in 2020. This discussion follows the acquisition of Instadeep by German biotech firm BioNTech for over $550 million in January 2023. The collaboration aims to leverage scalable AI systems to address complex biological challenges, with a focus on enhancing vaccine and therapeutic development. BioNTech and Instadeep are working on advancing their AI models, increasing parameters from 150 million to 15 billion, which is expected to improve performance on various biological tasks.